Clinical Trials Browser

INDUSTRY × Breast Neoplasms × tucatinib × Clear all

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05132582 2026-03-16

HER2CLIMB-05

Phase 3 Active not recruiting

654 enrolled

Breast

Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1 Active not recruiting

25 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

81 enrolled

Breast

Breast Neoplasms

NCT05458674 2026-01-12

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Completed

86 enrolled

Breast

Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04539938 2025-09-30

HER2CLIMB-04

Phase 2 Completed

70 enrolled 11 charts

Breast

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast

Breast Neoplasms

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

279 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 2 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT01983501 2020-09-21

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Phase 1 Completed

57 enrolled

Breast

Breast Neoplasms

NCT02025192 2020-06-04

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Phase 1 Completed

60 enrolled

Breast

Breast Neoplasms

NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

No longer available

BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Clinical Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

HER2CLIMB-05

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

MK-1022-009

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

MK-7119-001

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

DB-07

HER2CLIMB-04

PIKture-01

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

HER2CLIMB

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer